# Discounted Drugs for Clinical Trials Act

This bill makes it easier and cheaper for people to participate in medical research studies by allowing pharmaceutical companies to provide discounted or free drugs to patients enrolled in clinical trials. Right now, when drug companies test new medications on human subjects, they often charge full price for the experimental drugs, which can be extremely expensive and may prevent people from participating in these studies. This bill removes barriers that make it hard for patients to afford these trial medications.

The practical effect is that more people could potentially join clinical trials without facing financial hardship. If you're dealing with a serious illness and a clinical trial offers a promising new treatment, you wouldn't have to worry as much about the cost of the experimental drug itself. This could speed up the drug development process because researchers would have an easier time recruiting enough participants for their studies. It also means patients get access to cutting-edge treatments they might not otherwise be able to afford, while drug companies get the human testing data they need to eventually bring new medicines to market.

The bill essentially recognizes that cost is a major obstacle keeping sick people out of research studies. By allowing companies to offer these drugs at reduced or no cost during trials, it creates a win-win situation: patients get potential access to new treatments, and researchers get the participants they need to properly test whether those treatments actually work. This could ultimately lead to new medicines reaching patients faster and being more thoroughly tested before they become widely available.

Discounted Drugs for Clinical Trials Act

Stabenow, Debbie

Discounted Drugs for Clinical Trials Act This bill allows researchers to obtain certain high-cost drugs and biologics at discounted prices from manufacturers. Researchers must apply to the Food and Drug Administration for approval; manufacturers must sell the approved quantity of drugs to researchers at the discounted price and are subject to civil actions from researchers for noncompliance.